Summary for Clinicians: 2019 Clinical Practice Guideline Summary for the Treatment of Drug-Resistant Tuberculosis

Ann Am Thorac Soc. 2020 Aug;17(8):911-917. doi: 10.1513/AnnalsATS.202004-318CME.

Authors

Christopher A Berger¹, Narges Alipanah¹, Fayez Kheir², Joseph K Ruminjo³, Payam Nahid¹, Carey Thomson^{4

5}

Affiliations

¹ Division of Pulmonary and Critical Care Medicine, Department of Medicine, UCSF Center for Tuberculosis, University of California, San Francisco, California.
² Tulane University School of Medicine, New Orleans, Louisiana.
³ American Thoracic Society, New York, New York.
⁴ Division of Pulmonary and Critical Care, Department of Medicine, Mount Auburn Hospital, Cambridge, Massachusetts; and.
⁵ Harvard Medical School, Boston, Massachusetts.

PMID: 32464069
DOI: 10.1513/AnnalsATS.202004-318CME

No abstract available

Keywords: MDR-TB; drug treatment; duration of treatment; treatment monitoring; tuberculosis.

Publication types

Practice Guideline
Review

MeSH terms

Antitubercular Agents / administration & dosage*
Drug Administration Schedule
Drug Therapy, Combination
Humans
Tuberculosis, Multidrug-Resistant / diagnosis*
Tuberculosis, Multidrug-Resistant / drug therapy*
Tuberculosis, Multidrug-Resistant / microbiology
Tuberculosis, Pulmonary / diagnosis*
Tuberculosis, Pulmonary / drug therapy*
Tuberculosis, Pulmonary / microbiology

Substances

Antitubercular Agents